Robust NDA submission supported by data from two highly statistically significant Phase 3 trials and a Phase 2b study that each met its primary endpoint and involved a total of more than 1,000 participants living with
Compass Pathways plc (NASDAQ:CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass
Compass Pathways plc (NASDAQ:CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that management will attend the Stifel 2026 Healthcare
Final NDA submission nearing completion and will be filed in the next two weeks
Launch readiness on track for expected launch in H12027, subject to FDA approval
Data from two positive Phase 3 trials reinforce
New survey findings reveal the extent of unmet need for people living with treatment-resistant depression (TRD) and its impact on families, relationships and the ability to participate fully in everyday
Disease education booth underscores continued commitment to advancing understanding of treatment-resistant depression (TRD) among U.S. healthcare professionals (HCPs)
Encore poster presentations highlight key
Compass Pathways plc (NASDAQ:CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that it will release financial results for the third
First-ever Treatment-Resistant Depression (TRD) Awareness Day establishes dedicated moment to recognize and raise awareness of the condition’s profound impact on patients and their loved ones
Survey data in a new
Compass Pathways plc (NASDAQ:CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass
Compass Pathways plc (NASDAQ:CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced the appointment of Kelley Boucher as Chief People Officer,
Compass Pathways plc (NASDAQ:CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that management will attend the TD Cowen 6th Annual Novel
New U.S. healthcare provider (HCP) disease education initiative, Change the Tune in TRD explores the neurobiology and care pathways to support greater recognition and understanding of treatment-resistant depression
Strata’s implementation platform includes provider training, certification, site readiness, and ongoing clinical support; its founders worked with Compass on the COMP360 training program for clinicians, who supported
New certificate program will prepare clinicians to support patients receiving COMP360 psilocybin treatment, if approved by the FDANEW YORK, Sept. 10, 2026 /PRNewswire/ -- Fluence, a leading provider of professional
Five organizations awarded grants, above the planned three, as a result of a competitive selection process with highly qualified applicants
Training guidance is designed to prepare healthcare providers to deliver
